Blog
Published January 17, 2025
One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments (HTA). Trinity presented 11 posters at ISPOR EU, 6 of which focused on HTA and/or JCA.
JCA is an EU initiative intended to improve patient access to health technologies in Europe through a harmonized clinical HTA process. Beginning in January…
Read Now
Blog
Published January 10, 2025
Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence and high costs. As cell and gene therapies become available in new indications beyond oncology and rare pediatric diseases, developers of innovative therapies need to develop strategies targeting patients, providers and payers to overcome these challenges and promote access…
Read Now
Blog
Published January 6, 2025
In today’s fast-paced business environment, the ability to harness data effectively can be a game-changer. Companies that can quickly integrate and analyze data from various sources are better positioned to make informed decisions, optimize operations and stay ahead of the competition.
The complexity of managing diverse data sources, ensuring data quality and maintaining consistent performance metrics can be daunting. These challenges are often exacerbated during periods of rapid growth, such as when a company is acquiring new businesses and integrating…
Read Now
Blog
Published December 12, 2024
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics market environment, including the trends below, to determine implications for payers and manufacturers and help them prepare for the year ahead.
Key Trends
Continued Emphasis…
Read Now
Blog
Published December 10, 2024
79% of respondents are predicting an increase in spend in Omnichannel capabilities for Medical Affairs in 2025, according to a recent TGaS survey fielded in September 2024.*
This predicted increase for Medical Omnichannel indicates that there is a real need to find ways to inform, educate and engage HCPs beyond the traditional in-person channel.
What is Medical Omnichannel?
Medical omnichannel is an orchestrated approach to scientific engagement, leveraging analytics and insights to optimize educational content and channels in a customer-centric…
Read Now
Blog
Published November 12, 2024
Trinity Life Sciences recently attended the HLTH 2024 conference in Las Vegas. The conference focused on “pushing boundaries to transform the next decade of health” and united stakeholders across the entire healthcare ecosystem, including life sciences professionals, providers, payers, government, healthcare policymakers, investors and more. Trinity’s Customer Engagement team participated in workshops and discussions to hear the latest from our peers, other industry leaders and sponsors – here are our key takeaways from HTLH 2024:
Moving from Multichannel to Omnichannel …
Read Now
Blog
Published November 5, 2024
What is data operationalization, and why is it important in life sciences?
The ability to integrate insights from your data into your business workflows is commonly referred to as data operationalization.
Throughout life sciences organizations, functional needs and behaviors have evolved, making data operationalization at scale a vital source of competitive advantage for life sciences.
It is no longer enough to derive business strategy from data to ensure a competitive advantage. Executives now expect real-time updates from the market—and patients…
Read Now
Blog
Published October 1, 2024
The customer is changing
The landscape around life sciences is more competitive than ever, with a shorter runway to success and market dynamics (payer, competition, etc.) that are indisputably changing the role and level of influence at a customer level. These changes are happening at a hyper-local level, not just at a homogenous national level. And it is this shift in control and influence locally that causes complexity for pharma to identify, prioritize, reach and engage key customers. Personalized, customer-centric…
Read Now
Blog
Published September 25, 2024
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).
PNH is a rare genetic blood disorder in which the patient’s immune system attacks and destroys red blood cells and platelets. As the disease progresses, it can lead to severe complications that may become life-threatening. PNH is listed in the first edition of China’s rare disease catalog, with…
Read Now
Blog
Published September 17, 2024
What does orchestration mean for a brand?
True orchestration considers a customer’s preferences before communicating with them. Learnings from past interactions and outcomes are used to identify the most relevant action to lead to a rewarding experience for both the customer and the brand. Orchestration can be defined as all channels learning from each other to create better “surround sound” for the customer.
Orchestration for a brand means that you have a thoughtfully-built decision engine that can process historical customer…
Read Now
